{"id":560,"date":"2019-12-23T20:30:00","date_gmt":"2019-12-23T11:30:00","guid":{"rendered":"https:\/\/idsc-gunma.jp\/congress\/jstm\/?p=560"},"modified":"2022-05-26T20:26:26","modified_gmt":"2022-05-26T11:26:26","slug":"%e3%83%8f%e3%82%a4%e3%83%91%e3%83%bc%e3%82%b5%e3%83%bc%e3%83%9f%e3%82%a2%e3%82%92%e7%94%a8%e3%81%84%e3%81%9fbrca%e7%99%ba%e7%8f%be%e8%85%ab%e7%98%8d%e7%b4%b0%e8%83%9e%e3%81%ab%e3%81%8a%e3%81%91","status":"publish","type":"post","link":"https:\/\/idsc-gunma.jp\/congress\/jstm\/%e3%83%8f%e3%82%a4%e3%83%91%e3%83%bc%e3%82%b5%e3%83%bc%e3%83%9f%e3%82%a2%e3%82%92%e7%94%a8%e3%81%84%e3%81%9fbrca%e7%99%ba%e7%8f%be%e8%85%ab%e7%98%8d%e7%b4%b0%e8%83%9e%e3%81%ab%e3%81%8a%e3%81%91\/","title":{"rendered":"\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3092\u7528\u3044\u305fBRCA\u767a\u73fe\u816b\u760d\u7d30\u80de\u306b\u304a\u3051\u308bPARP\u963b\u5bb3\u5264\u304a\u3088\u3073\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u306b\u3088\u308b\u5408\u6210\u81f4\u6b7b\u306e\u5897\u5f37\u304a\u3088\u3073\u653e\u5c04\u7dda\u5897\u611f\u4f5c\u7528\u306b\u3064\u3044\u3066"},"content":{"rendered":"\n<p>\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306b\u95a2\u3059\u308b\u6700\u8fd1\u306e\u8a71\u984c35&nbsp;<\/p>\n\n\n\n<p><strong>\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3092\u7528\u3044\u305fBRCA\u767a\u73fe\u816b\u760d\u7d30\u80de\u306b\u304a\u3051\u308bPARP\u963b\u5bb3\u5264\u304a\u3088\u3073\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u306b\u3088\u308b\u5408\u6210\u81f4\u6b7b\u306e\u5897\u5f37\u304a\u3088\u3073\u653e\u5c04\u7dda\u5897\u611f\u4f5c\u7528\u306b\u3064\u3044\u3066<\/strong><\/p>\n\n\n\n<p>\u8fd1\u85e4\u3000\u9686\uff08\u5bcc\u5c71\u5927\u5b66\u5927\u5b66\u9662\u533b\u5b66\u85ac\u5b66\u7814\u7a76\u90e8<strong>\uff09<\/strong><\/p>\n\n\n\n<p>\u6700\u8fd1\uff0c\u8907\u6570\u306e\u907a\u4f1d\u5b50\u306e\u6b20\u640d\u304c\u5171\u5b58\u3059\u308b\u3068\u81f4\u6b7b\u6027\u3092\u767a\u63ee\u3059\u308b\u73fe\u8c61\u3067\u3042\u308b\u5408\u6210\u81f4\u6b7b (Synthetic lethality)\u304c\u764c\u6cbb\u7642\u306e\u6a19\u7684\u3068\u3057\u3066\u6ce8\u76ee\u3055\u308c\u3066\u3044\u308b\uff0e\u4eca\u56de\u7d39\u4ecb\u3059\u308b\u30aa\u30e9\u30f3\u30c0\u306eAcademic Medical Center\u3092\u4e2d\u5fc3\u3068\u3057\u305f\u30b0\u30eb\u30fc\u30d7\u306fPARP (Poly(ADP-ribose) polymerase)1\u963b\u5bb3\u5264 (PARP1-<em>i<\/em>)\u3092\u7528\u3044\uff0c\u5408\u6210\u81f4\u6b7b\u3092\u6a19\u7684\u306b\u3057\u305f\u6e29\u71b1\u7642\u6cd5\u306b\u3064\u3044\u3066\u7814\u7a76\u3092\u3057\u3066\u3044\u308b\uff0ePARP1\u306fDNA\u8907\u88fd\u3092\u53f8\u308b\u91cd\u8981\u306a\u9175\u7d20\u3067\u3042\u308b\uff0e\u305d\u306e\u305f\u3081PARP1\u306e\u963b\u5bb3\u306f\u8907\u88fd\u30d5\u30a9\u30fc\u30af\u5f62\u6210\u3092\u963b\u5bb3\u3057\uff0c\u907a\u4f1d\u7684\u4e0d\u5b89\u5b9a\u6027\u3092\u62db\u304d\uff0cDNA\u4e8c\u672c\u9396\u5207\u65ad\u3092\u8a98\u767a\u3057\u3084\u3059\u304f\u3057\uff0c\u7d50\u679c\u3068\u3057\u3066\u7d30\u80de\u6b7b\u3092\u8a98\u5c0e\u3059\u308b\uff0ePARP1\u963b\u5bb3\u306b\u3088\u308bDNA\u640d\u50b7\u306f\uff0cBRCA2 (breast cancer susceptibility gene II) \u30bf\u30f3\u30d1\u30af\u8cea\u3092\u5fc5\u8981\u3068\u3059\u308bHR (homologous recombination, \u76f8\u540c\u7d44\u63db\u3048)\u3067\u4fee\u5fa9\u3055\u308c\u308b\uff0e\u5f7c\u3089\u306f\u307e\u305a41\u301c42.5\u2103\u306e\u30de\u30a4\u30eb\u30c9\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2(HT)\u306fBRCA2\u306e\u5206\u89e3\u3092\u4fc3\u9032\u3059\u308b\u3053\u3068\u3067\u4e00\u6642\u7684\u306b\u305d\u306e\u767a\u73fe\u3092\u4f4e\u4e0b\u3055\u305b\u308b\u306e\u3067\uff0cHR\u3092\u6570\u6642\u9593\u3060\u3051\u963b\u5bb3\u3057\uff0c\u305d\u306e\u7d50\u679c\u6cbb\u7642\u5bfe\u8c61\u306e\u816b\u760d\u306b\u5408\u6210\u81f4\u6b7b\u6761\u4ef6\u3092\u8a98\u5c0e\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u308b\u3053\u3068\u3092\u793a\u3057\u305f<sup>1)<\/sup>\uff0e\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u306fHT\u3068\u306e\u4f75\u7528\u3067\u305d\u306e\u52b9\u679c\u3092\u5897\u5f37\u3059\u308b\u3053\u3068\u306f\u77e5\u3089\u308c\u3066\u304a\u308a\uff0c\u5f7c\u3089\u306f\u3055\u3089\u306bPARP1-<em>i<\/em>&nbsp;(NU1025\uff0cTocris Bioscience, Bristol, UK)\u3092\u4f75\u7528\u3057\u305f\u5834\u5408\u306e\u7d30\u80de\u81f4\u6b7b\u304a\u3088\u3073\u816b\u760d\u5897\u6b96\u9045\u5ef6\u52b9\u679c\u306b\u3064\u3044\u3066\u8abf\u3079\u305f\uff0e\u7d30\u80de\u3068\u3057\u3066HR\u6a5f\u80fd\u3092\u6709\u3059\u308b\u30e9\u30c3\u30c8\u6a2a\u7d0b\u7b4b\u8089\u816bR1, \u30d2\u30c8\u5b50\u5bae\u981a\u304c\u3093SiHa\u304a\u3088\u3073 HeLa\u7d30\u80de\u306e3\u7a2e\u985e\u3092\u7528\u3044\u305f\uff0e3\u7a2e\u3068\u3082HT\u51e6\u7406\uff0842\u2103, 1\u6642\u9593\uff09\u3067BRCA2\u767a\u73fe\u306f\u4f4e\u4e0b\u3057\u305f\uff0e\u7d30\u80de\u5468\u671f\u89e3\u6790\uff0c\u03b3H2AX\u30d5\u30a9\u30fc\u30ab\u30b9\uff0c\u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\u304a\u3088\u3073\u751f\u5b58\u7387\u3092\u8abf\u3079\u305f\u3068\u3053\u308d\uff0cPARP1-<em>i<\/em>\u3068\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u304a\u3088\u3073HT (42\u2103\uff0c1\u6642\u9593)\u3068\u306e\u4f75\u7528\u3067\u306f\u751f\u5b58\u7387\u306f\u6e1b\u5c11\u3057\uff0c\u3053\u306e\u6a5f\u5e8f\u306fDNA\u640d\u50b7\u306e\u5897\u52a0\u3068DNA\u4fee\u5fa9\u306e\u4f4e\u4e0b\u3067\u8aac\u660e\u3067\u304d\u308b\uff0eR1\u7d30\u80de\u3092\u79fb\u690d\u3057\u305f\u30e9\u30c3\u30c8\u816b\u760d\u30e2\u30c7\u30eb\u3067\u3082\u540c\u69d8\u306b\u6cbb\u7642\u5897\u5f37\u52b9\u679c\u304c\u5f97\u3089\u308c\u305f\uff0eHR\u6a5f\u80fd\u3092\u4fdd\u6301\u3057\u305f\u7d30\u80de\u3067\u3082\u6709\u610f\u306a\u5897\u5f37\u52b9\u679c\u304c\u5f97\u3089\u308c\u305f\u3053\u3068\u3088\u308a\uff0cPARP1-<em>i<\/em>\u3068\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u3092\u7528\u3044\u305f\u6e29\u71b1\u5316\u5b66\u7642\u6cd5\u306fHR\u6a5f\u80fd\u306e\u6709\u7121\u306b\u4fc2\u308f\u3089\u305a\uff0c\u6709\u52b9\u306a\u764c\u6cbb\u7642\u3068\u306a\u308b\u3053\u3068\u304c\u793a\u5506\u3055\u308c\u305f<sup>2)<\/sup>\uff0e<\/p>\n\n\n\n<p>\u6b21\u306b\u5f7c\u3089\u306f<em>BRCA2<\/em>\u4fdd\u6709\u304a\u3088\u3073\u6b20\u640d\u306e\u54042\u7a2e\u306e\u7d30\u80de\u306e\u6e29\u71b1\u306b\u3088\u308b\u653e\u5c04\u7dda\u5897\u611f\u52b9\u679c\u306b\u52a0\u3048\u3066PARP1-<em>i<\/em>\u4f75\u7528\u52b9\u679c\u306b\u3064\u3044\u3066\u8abf\u3079\u305f\uff0e<em>BRCA2<\/em>\u4fdd\u6709\u304a\u3088\u3073\u6b20\u640d\u7d30\u80de\u306ePARP1-<em>i<\/em>\u6bd2\u6027\u3092\u8abf\u3079\u305f\u3068\u3053\u308d\uff0c\u6b20\u640d\u7d30\u80de\u304c\u9ad8\u3044\u611f\u53d7\u6027\u3092\u793a\u3057\u305f\uff0eBRCA2\u72b6\u614b\u306b\u3088\u3089\u305aHT\uff0842\u2103, 1\u6642\u9593\uff09\u306f\u653e\u5c04\u7dda\u5897\u611f\u3057\u305f\u304c\uff0cPARP1-<em>i<\/em>\u4f75\u7528\u5897\u611f\u52b9\u679c\u306f<em>BRCA2<\/em>\u4fdd\u6709\u7d30\u80de\u3067\u9ad8\u304b\u3063\u305f\uff0e\u307e\u305f\uff0c\u5168\u3066\u306e\u7d30\u80de\u7fa4\u3067\uff0cHT\u3068\u653e\u5c04\u7dda\u304a\u3088\u3073PARP1-<em>i<\/em>\u306e3\u8005\u4f75\u7528\u306f2\u8005\u4f75\u7528\u306b\u6bd4\u3079\u3066\u6700\u4f4e\u306e\u751f\u5b58\u7387\uff0c\u6700\u9ad8\u306eDNA\u640d\u50b7\u304a\u3088\u3073\u30a2\u30dd\u30c8\u30fc\u30b7\u30b9\u751f\u6210\u3092\u793a\u3057\u305f\uff0e\u3053\u308c\u3089\u306e\u7d50\u679c\u3088\u308aHT\u306fHR\u306e\u963b\u5bb3\u306b\u52a0\u3048\u3066\uff0c<em>BRCA2<\/em>\u6b20\u640d\u7d30\u80de\u306b\u304a\u3044\u3066\u3082\u653e\u5c04\u7dda\u5897\u611f\u306b\u5bc4\u4e0e\u3059\u308b\u3053\u3068\uff0cPARP1-<em>i<\/em>\u3092\u7528\u3044\u305f3\u8005\u4f75\u7528\u306fBRCA2\u72b6\u614b\u306b\u3088\u3089\u305a\uff0c\u5168\u3066\u306e\u60a3\u8005\u306b\u6709\u52b9\u3067\u3042\u308b\u53ef\u80fd\u6027\u304c\u793a\u3055\u308c\u305f<sup>3)<\/sup>\uff0e<\/p>\n\n\n\n<p>\u672c\u5e74\u306eNature\u306e\u7dcf\u8aac\u306b\u304c\u3093\u306b\u304a\u3051\u308b\u85ac\u5264\u62b5\u6297\u6027\u306b\u3064\u3044\u3066\u5bfe\u7b56\u304c\u53d6\u308a\u4e0a\u3052\u3089\u308c\u3066\u3044\u308b<sup>4)<\/sup>\uff0e\u3053\u306e\u89e3\u6c7a\u7b56\u3068\u3057\u3066\u2460\u304c\u3093\u5316\u963b\u6b62\u3092\u53ef\u80fd\u306b\u3059\u308b\u65e9\u671f\u306e\u816b\u760d\u767a\u898b\uff0c\u2461\u6cbb\u7642\u4e2d\u306e\u9069\u5fdc\u7684\u30e2\u30cb\u30bf\u30ea\u30f3\u30b0\uff0c\u2462\u3088\u308a\u9ad8\u3044\u594f\u529f\u3092\u3082\u305f\u3089\u3059\u65b0\u898f\u85ac\u5264\u3084\u6539\u826f\u85ac\u7406\u5b66\u7684\u6307\u91dd\u306e\u8ffd\u52a0\uff0c\u306b\u7d9a\u3044\u3066\uff0c\u2463\u30cf\u30a4\u30b9\u30eb\u30fc\u30d7\u30c3\u30c8\u306e\u5408\u6210\u81f4\u6b7b\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3084\u81e8\u5e8a\u30b2\u30ce\u30e0\u30c7\u30fc\u30bf\u306e\u7d71\u5408\uff0c\u6570\u7406\u30e2\u30c7\u30eb\u5316\u306b\u3088\u308b\u304c\u3093\u7d30\u80de\u4f9d\u5b58\u6027\u306e\u7279\u5b9a\u304c\u6319\u3052\u3089\u308c\u3066\u304a\u308a\uff0c\u5408\u6210\u81f4\u6b7b\u306f\u85ac\u5264\u62b5\u6297\u6027\u306e\u514b\u670d\u306b\u304a\u3044\u3066\u3082\u91cd\u8981\u3067\u3042\u308b\uff0e\u4eca\u5f8c\u3068\u3082\uff0c\u5408\u6210\u81f4\u6b7b\u3092\u6a19\u7684\u3068\u3057\u305f\u3088\u308a\u9078\u629e\u6027\u306e\u9ad8\u3044\u85ac\u5264\u958b\u767a\u3068\u3068\u3082\u306b\u6e29\u71b1\u306e\u5bc4\u4e0e\u306b\u3064\u3044\u3066\u3082\u7814\u7a76\u304c\u9032\u3080\u3053\u3068\u304c\u671f\u5f85\u3055\u308c\u308b\uff0e<\/p>\n\n\n\n<p>\u53c2\u8003\u6587\u732e<\/p>\n\n\n\n<p>1)\u3000Krawczyk PM,&nbsp;<em>et al.<\/em>&nbsp;Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.<\/p>\n\n\n\n<p>\u3000\u3000Proc Natl Acad Sci U S A, 108: 9851-6, 2011.<\/p>\n\n\n\n<p>2)\u3000Oei AL,&nbsp;<em>et al<\/em>. Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia. Oncotarget, 8: 28116-24, 2017.<\/p>\n\n\n\n<p>3)\u3000Oei AL,&nbsp;<em>et al<\/em>. Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i. Int J Hyperthermia, 34: 39-48,2018.<\/p>\n\n\n\n<p>4)\u3000Vasan N,<em>&nbsp;et al<\/em>. A view on drug resistance in cancer. Nature, 575: 299-309,2019.<\/p>\n\n\n\n<p>\u7528\u8a9e\u89e3\u8aac<\/p>\n\n\n\n<p>\u5408\u6210\u81f4\u6b7b(\u6027) (Synthetic lethality): \u5358\u72ec\u907a\u4f1d\u5b50\u6b20\u640d\u3067\u306f\u7d30\u80de\u3084\u500b\u4f53\u306b\u5bfe\u3059\u308b\u81f4\u6b7b\u6027\u3092\u793a\u3055\u306a\u3044\u306e\u306b\uff0c\u8907\u6570\u306e\u907a\u4f1d\u5b50\u306e\u6b20\u640d\u304c\u5171\u5b58\u3059\u308b\u3068\u81f4\u6b7b\u6027\u3092\u767a\u63ee\u3059\u308b\u73fe\u8c61\uff0e\u300c\u5408\u6210\u81f4\u6b7b\u300d\u5206\u91ce\u306e\u597d\u4f8b\u3067\u3042\u308bPARP\u963b\u5bb3\u85ac\u306f\uff0c\u4e00\u672c\u9396DNA\u640d\u50b7\u3092\u4fee\u5fa9\u3059\u308b\u6a5f\u80fd\u3092\u6301\u3064PARP\u3068\u4e8c\u672c\u9396DNA\u306e\u640d\u50b7\u3092\u4fee\u5fa9\u3059\u308bBRCA\u3092\u6cbb\u7642\u6a19\u7684\u3068\u3057\u305f\u85ac\u5264\u3067\u3042\u308b\uff0e\u672c\u90a6\u3067\u306f<em>BRCA<\/em>\u907a\u4f1d\u5b50\u5909\u7570\u967d\u6027\u306e\u5375\u5de3\u764c\u3092\u5bfe\u8c61\u306b\u3057\u305fAstraZeneca\u793e\u306eLynparza (Olaparib)\u304c2018\u5e74\u306b\u8a8d\u53ef\u3055\u308c\u305f\uff0eDNA\u640d\u50b7\u304c\u8d77\u304d\u305f\u969b\uff0c\u4f55\u3089\u304b\u306e\u539f\u56e0\u3067PARP\u304c\u6a5f\u80fd\u3057\u306a\u3044\u5834\u5408\u3067\u3082BRCA\u304c\u6a5f\u80fd\u3059\u308c\u3070DNA\u640d\u50b7\u306f\u4fee\u5fa9\u3055\u308c\u308b\uff0e\u3057\u304b\u3057\uff0c<em>BRCA<\/em>\u306b\u5909\u7570\u304c\u3042\u308aBRCA\u304c\u6a5f\u80fd\u3057\u306a\u3044\u7d30\u80de\u3067PARP\u3092\u963b\u5bb3\u3059\u308b\u3068\u7d30\u80de\u6b7b\u304c\u8d77\u304d\u308b\uff0e\u3053\u306e\u3088\u3046\u306b\uff0c\u4f5c\u7528\u6a5f\u5e8f\u304c\u660e\u78ba\u304b\u3064\u52b9\u679c\u304c\u793a\u3055\u308c\u3066\u3044\u308b\u3053\u3068\u304b\u3089\uff0c\u300c\u5408\u6210\u81f4\u6b7b\u300d\u5206\u91ce\u306e\u533b\u85ac\u54c1\u306e\u958b\u767a\u304c\u76db\u3093\u306b\u884c\u308f\u308c\u3066\u3044\u308b\uff0e<\/p>\n\n\n\n<p>PARP (Poly(ADP-ribose) polymerase) 1: \u30dd\u30eaADP-\u30ea\u30dc\u30b7\u30eb\u5316\u53cd\u5fdc\u3092\u89e6\u5a92\u3059\u308b\u9175\u7d20\uff0e\u672c\u53cd\u5fdc\u306f\u771f\u6838\u751f\u7269\u306b\u7279\u7570\u7684\u306a\u53ef\u9006\u7684\u7ffb\u8a33\u5f8c\u4fee\u98fe\u3067\u3042\u308a\uff0cDNA\u4fee\u5fa9\uff0c\u8ee2\u5199\u8abf\u7bc0\uff0c\u7d30\u80de\u6b7b\uff0c\u4e2d\u5fc3\u4f53\u306e\u5206\u88c2\u5236\u5fa1\u306a\u3069\uff0c\u6838\u5185\u306b\u304a\u3051\u308b\u591a\u304f\u306e\u6a5f\u80fd\u306b\u95a2\u4e0e\u3057\u3066\u3044\u308b\uff0eDNA\u4fee\u5fa9\u306b\u95a2\u3057\u3066PARP\u306f\uff0c\u6838DNA\u306b\u751f\u3058\u305f\u4e00\u672c\u9396\u5207\u65ad\u7aef\u3092\u8a8d\u8b58\u3057\u3066DNA\u306b\u7d50\u5408\u3059\u308b\uff0e\u6838DNA\u306b\u7d50\u5408\u3057\u305fPARP\u306f\u6d3b\u6027\u5316\u3055\u308c\uff0c\u30cb\u30b3\u30c1\u30f3\u30a2\u30df\u30c9\u30a2\u30c7\u30cb\u30f3\u30b8\u30cc\u30af\u30ec\u30aa\u30c1\u30c9 (NAD<sup>\uff0b<\/sup>)\u3092\u57fa\u8cea\u3068\u3057\u3066PARP\u81ea\u8eab\u3084DNA\u4fee\u5fa9\u95a2\u9023\u30bf\u30f3\u30d1\u30af\u8cea\u306bADP-\u30ea\u30dc\u30fc\u30b9\u3092\u4ed8\u52a0\u3057\uff0c\u30dd\u30ea-ADP-\u30ea\u30dc\u30b7\u30eb\u5316\u3092\u5f15\u304d\u8d77\u3053\u3059\uff0e\u3053\u308c\u306b\u3088\u308aDNA\u4fee\u5fa9\u53cd\u5fdc\u3092\u6d3b\u6027\u5316\u3059\u308b.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u306b\u95a2\u3059\u308b\u6700\u8fd1\u306e\u8a71\u984c35&nbsp; \u30cf\u30a4\u30d1\u30fc\u30b5\u30fc\u30df\u30a2\u3092\u7528\u3044\u305fBRCA\u767a\u73fe\u816b\u760d\u7d30\u80de\u306b\u304a\u3051\u308bPARP\u963b\u5bb3\u5264\u304a\u3088\u3073\u30b7\u30b9\u30d7\u30e9\u30c1\u30f3\u306b\u3088\u308b\u5408\u6210\u81f4\u6b7b\u306e\u5897\u5f37\u304a\u3088\u3073\u653e\u5c04\u7dda\u5897\u611f\u4f5c\u7528\u306b\u3064\u3044\u3066 \u8fd1\u85e4\u3000\u9686\uff08\u5bcc\u5c71\u5927\u5b66\u5927\u5b66\u9662\u533b\u5b66\u85ac\u5b66\u7814 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"vkexunit_cta_each_option":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-560","post","type-post","status-publish","format-standard","hentry","category-report"],"_links":{"self":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/560","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/comments?post=560"}],"version-history":[{"count":1,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/560\/revisions"}],"predecessor-version":[{"id":561,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/posts\/560\/revisions\/561"}],"wp:attachment":[{"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/media?parent=560"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/categories?post=560"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idsc-gunma.jp\/congress\/jstm\/wp-json\/wp\/v2\/tags?post=560"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}